Modern ethical aspects of clinical trials in patients with multiple sclerosis
- Authors: Ivashkova E.V.1, Petrov A.M.1, Votintseva M.V.1, Shkilnyuk G.G.1, Stolyarov I.D.1
-
Affiliations:
- N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences
- Issue: Vol 6, No 2 (2012)
- Pages: 32-37
- Section: Reviews
- URL: https://ogarev-online.ru/2075-5473/article/view/124536
- DOI: https://doi.org/10.17816/psaic272
- ID: 124536
Cite item
Full Text
Abstract
In this article, universal guidelines and requirements to clinical trials of new drugs in multiple sclerosis are presented. Principles of patients’ informed consent, various ethical aspects and possible problems occurring in the course of clinical trials in these patients are discussed in detail. Presented are main current documents regulating clinical trials of new drugs in the Russian Federation.
About the authors
E. V. Ivashkova
N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences
Email: petrov@ihb.spb.ru
Russian Federation, St. Petersburg
A. M. Petrov
N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences
Author for correspondence.
Email: petrov@ihb.spb.ru
Russian Federation, St. Petersburg
M. V. Votintseva
N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences
Email: petrov@ihb.spb.ru
Russian Federation, St. Petersburg
G. G. Shkilnyuk
N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences
Email: petrov@ihb.spb.ru
Russian Federation, St. Petersburg
I. D. Stolyarov
N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences
Email: petrov@ihb.spb.ru
Russian Federation, St. Petersburg
References
- Бойко А.Н., Столяров И.Д., Петров А.М. и др. Перспективы новых методов патогенетической терапии рассеянного склероза. Неврол. вестник 2010; 1: 157–159.
- Малышева Е.А., Мохов О.И.Информированное согласие в клинических испытаниях лекарственных средств. Качественная клиническая практика 2002; 1: 1–5.
- Рассеянный склероз и другие демиелинизирующие заболевания (под ред. Е.И. Гусева, И.А. Завалишина, А.Н. Бойко). М.: Миклош, 2004.
- Рассеянный склероз: диагностика, лечение, специалисты (под ред. И.Д. Столярова, А.Н. Бойко). СПб: Элби-СПб, 2008.
- Приказ Министерства здравоохранения и социального развития Российской Федерации от 31 августа 2010 г. № 774н «О Совете по этике».
- Федеральный закон от 12.04.2010 № 61-ФЗ «Об обращении лекарственных средств».
- Хельсинкская декларация Всемирной медицинской ассоциации: рекомендации для врачей по проведению биомедицинских исследований на людях. М., 2008.
- Comi G., Abramsky O., Arbizu T. et al. Oral laquinimod in patients with relapsing-remitting MS: 9-month double-blind active extension of the multicentre, randomized, double-blind, parallel-group placebocontrolled study. Multiple Sclerosis 2008; 14: 27–31.
- Emanuel E.J., Wendler D., Grady C. What makes clinical research ethical? JAMA 2000; 283: 2701–2711.
- EMEA need for Revision of the Note for Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis, 2005.
- Kappos L., Radue E.W., O’Connor P. et al. Oral fingolimod in patients with relapsing MS: 3-year results from a phase II study extension. Multiple Sclerosis 2008; 14 (Suppl. 1): P72.
- Lublin F.D. Placebo-controlled clinical trials in multiple sclerosis: Ethical Considerations. Ann. Neurol. 2001; 49: 677–681.
- O’Connor P., Confavreux C., Comi G. et al. Oral teriflunomide in patients with relapsing MS: baseline clinical features of patients in the TEMSO phase III trial. Multiple sclerosis 2008; 14 (Suppl.1): S85.
- Polman C.H. Ethics of placebo controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2009; 72: 1191–1192.
- Pryse-Phillips W. Ethical considerations for clinical trial design in MS. The International MS Journal 2002; 9: 9–15.
Supplementary files
